[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1045529B - 基本上為結晶形式的美拉加群 - Google Patents

基本上為結晶形式的美拉加群

Info

Publication number
HK1045529B
HK1045529B HK02106968.3A HK02106968A HK1045529B HK 1045529 B HK1045529 B HK 1045529B HK 02106968 A HK02106968 A HK 02106968A HK 1045529 B HK1045529 B HK 1045529B
Authority
HK
Hong Kong
Prior art keywords
melagatran
crystalline form
substantially crystalline
crystalline
Prior art date
Application number
HK02106968.3A
Other languages
English (en)
Other versions
HK1045529A1 (en
Inventor
Lena HEDSTRÖM
Anita Lundblad
Sofia NÅGÅRD
Original Assignee
阿斯特拉曾尼卡有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿斯特拉曾尼卡有限公司 filed Critical 阿斯特拉曾尼卡有限公司
Publication of HK1045529A1 publication Critical patent/HK1045529A1/xx
Publication of HK1045529B publication Critical patent/HK1045529B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02106968.3A 1999-07-02 2002-09-24 基本上為結晶形式的美拉加群 HK1045529B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms
PCT/SE2000/001398 WO2001002426A1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran

Publications (2)

Publication Number Publication Date
HK1045529A1 HK1045529A1 (en) 2002-11-29
HK1045529B true HK1045529B (zh) 2007-02-23

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106968.3A HK1045529B (zh) 1999-07-02 2002-09-24 基本上為結晶形式的美拉加群

Country Status (33)

Country Link
US (1) US6479078B1 (zh)
EP (1) EP1196431B1 (zh)
JP (1) JP2003503508A (zh)
KR (1) KR20020020765A (zh)
CN (1) CN100537598C (zh)
AR (1) AR035553A1 (zh)
AT (1) ATE339438T1 (zh)
AU (1) AU765614B2 (zh)
BR (1) BR0012035A (zh)
CA (1) CA2376944A1 (zh)
CY (1) CY1107542T1 (zh)
CZ (1) CZ20014722A3 (zh)
DE (1) DE60030723T2 (zh)
DK (1) DK1196431T3 (zh)
EE (1) EE200100646A (zh)
ES (1) ES2270849T3 (zh)
HK (1) HK1045529B (zh)
HU (1) HUP0202322A3 (zh)
IL (1) IL146972A0 (zh)
IS (1) IS6215A (zh)
MX (1) MXPA01013441A (zh)
MY (1) MY122760A (zh)
NO (1) NO20016419L (zh)
NZ (1) NZ516187A (zh)
PL (1) PL352872A1 (zh)
PT (1) PT1196431E (zh)
RU (1) RU2243973C2 (zh)
SE (1) SE9902550D0 (zh)
SK (1) SK18832001A3 (zh)
TR (1) TR200103855T2 (zh)
TW (1) TWI250991B (zh)
WO (1) WO2001002426A1 (zh)
ZA (1) ZA200109944B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005051925A1 (ja) * 2003-11-27 2005-06-09 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶及びその製造方法
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
HUP0202322A2 (en) 2002-10-28
HUP0202322A3 (en) 2003-04-28
HK1045529A1 (en) 2002-11-29
ATE339438T1 (de) 2006-10-15
BR0012035A (pt) 2002-03-19
CN100537598C (zh) 2009-09-09
MY122760A (en) 2006-05-31
IS6215A (is) 2001-12-27
DE60030723T2 (de) 2007-11-08
JP2003503508A (ja) 2003-01-28
TWI250991B (en) 2006-03-11
CZ20014722A3 (cs) 2002-05-15
PT1196431E (pt) 2007-01-31
PL352872A1 (en) 2003-09-08
CN1359389A (zh) 2002-07-17
KR20020020765A (ko) 2002-03-15
CA2376944A1 (en) 2001-01-11
RU2243973C2 (ru) 2005-01-10
CY1107542T1 (el) 2013-03-13
ZA200109944B (en) 2003-03-03
AR035553A1 (es) 2004-06-16
SK18832001A3 (sk) 2002-10-08
NO20016419L (no) 2002-03-01
TR200103855T2 (tr) 2002-04-22
DE60030723D1 (de) 2006-10-26
NZ516187A (en) 2004-09-24
DK1196431T3 (da) 2006-12-11
MXPA01013441A (es) 2002-07-02
AU765614B2 (en) 2003-09-25
AU6040800A (en) 2001-01-22
NO20016419D0 (no) 2001-12-28
ES2270849T3 (es) 2007-04-16
WO2001002426A1 (en) 2001-01-11
IL146972A0 (en) 2002-08-14
SE9902550D0 (sv) 1999-07-02
US6479078B1 (en) 2002-11-12
EE200100646A (et) 2003-02-17
EP1196431A1 (en) 2002-04-17
EP1196431B1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
TW525477U (en) Compound napkin
HK1044768A1 (zh) 晶狀1-甲基碳青霉烯化合物
HRP20050176A2 (en) Novel processes for making - and a new crystalline form of-leflunomide
IL146972A0 (en) A substantially crystalline form of melagatran
GB9924797D0 (en) Compound
IL144757A0 (en) Eplerenone crystalline form
GB9920919D0 (en) Novel compound
AU140749S (en) A watch
GB9921928D0 (en) Compound
SI1196431T1 (sl) V bistvu kristalna oblika melagatrana
GB0031557D0 (en) Compound
GB9914342D0 (en) Compound
GB0031563D0 (en) Compound
GB9929255D0 (en) Compound
GB9921929D0 (en) Compound
GB2346143B (en) A compound
EP1209240A4 (en) CONNECTION F-15078
HU9904011D0 (en) Novel salts of dipeptid derivatives
GB0019884D0 (en) Watch having a lip-palette
GB2349386B (en) A compound
GB9924965D0 (en) Compound
GB9906874D0 (en) A compound
GB9922470D0 (en) A set of parts
GB9901166D0 (en) A set of parts
CA86455S (en) Case for a golfing aid

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110630